



Miltenyi Biotec

Generation of gene-engineered T cells via electroporation and/or transduction

CliniMACS Prodigy® T Cell Engineering

Application

Fully automated cell labeling, enrichment, activation, genetic engineering via electroporation and/or transduction and expansion of human T cells from patient material for production of gene-engineered T cells. The flexible combination of electroporation and transduction within one closed manufacturing process enables complex gene-editing applications.

This application sheet gives an overview of the specifications and materials needed to perform T cell engineering (TCE) on the CliniMACS Prodigy in combination with the CliniMACS® Electroporator. Furthermore, it illustrates the process workflow, as well as the configuration of the CliniMACS Prodigy Tubing Set, and provides performance data.

Specifications

Process name:	T Cell Engineering		
Selection capacity:	Up to 3×10^9 cells		
Sample volume for selection:	50–280 mL		
TransAct™ stimulation capacity:	0.2– 2×10^8 cells (2×10^8 recommended for electroporation)		
Electroporation pulses:	1st pulse	2nd pulse	
	Voltage (V)	50–1000	
	Length (µs)	5–100,000	
	Mode	Square, burst	
	Polarity	unipolar, bipolar	
	Burst length (µs)	5–100,000	5–100,000
Cell volume for electroporation:	20–157 mL		
Cell density for electroporation:	Recommended 1×10^7 cells/mL (1×10^6 to 5×10^7 cells/mL)		
Final product harvest volume:	Harvest type 1: 100 mL		
	Harvest type 2: up to 900 mL		
Process time:	10–14 days		

Products required*

Devices	Comment
CliniMACS Prodigy with T Cell Engineering	
CliniMACS Electroporator	For electroporation

CliniMACS and MACS GMP products	Comment
CliniMACS CD62L Reagent / GMP MicroBeads or CliniMACS CD4 and CD8 Reagent / GMP MicroBeads	For T cell isolation
CliniMACS Prodigy TS 520	
CliniMACS PBS/EDTA Buffer	For T cell isolation and optional cell wash
CliniMACS Electroporation Buffer	For electroporation
TexMACS® GMP Medium	For cell cultivation
MACS® GMP Recombinant Human IL-7 / IL-15 or IL-2	For cell cultivation
MACS GMP T Cell TransAct	For T cell activation

Additional material / equipment	Comment
Viral vector and/or nucleic acid or nucleoprotein complex to be electroporated	Depending on whether transduction and/or electroporation is desired
Triple Sampling Adapter (Miltenyi Biotec)	For additional sampling
Sterile water, syringes, hypodermic needles or Cytokine Vial Adapter (Miltenyi Biotec)	For cytokine reconstitution or For cytokine reconstitution in a closed system
MACS GMP Vectofusin-1 (Miltenyi Biotec)	For transduction, optional
Formulation solution (e.g. CliniMACS Formulation Solution)	For formulation of cells during harvest
Human Serum Albumin	For CliniMACS PBS/EDTA Buffer supplementation
Human AB serum	For addition to medium, optional
Sterile tube welder	For sterile tube connection
Uninterruptable power supply	As safety measurement
CO ₂ and compressed air supply	For cell cultivation
Cell counter and/or flow cytometer	For IPC and QC


*Depending on the chosen protocol some consumables might not be needed at all or in various amounts. Please contact your responsible Miltenyi Biotec representative for support.

Process overview


Pre-process	Tubing set installation ▼ Tubing set priming (buffer and medium) ▼
Enrichment	Enrichment preparation ▼ Enrichment CD4 / CD8 or CD62L ▼
Culture preparation	Connection of culture materials and entry of cultivation parameters ▼
Cultivation	Culture setup (rinsing with medium, cell seeding, activation) ▼ Cultivation with flexible activities (e.g. electroporation, feeding, media exchange, sampling, etc.) ▼
Post-process	Formulation and harvest ▼
Process time (approx.)	10–14 days

Table 1: Overview of the full T cell engineering process. When choosing the full process option, T cell enrichment, culture preparation and cultivation are performed. Other process options (so called cases) are available for flexible protocol adaption, e.g., option to start the process without T cell enrichment and process resume cases (not shown).

Principle of CliniMACS Prodigy T Cell Engineering



CliniMACS Prodigy TS 520 setup for T cell engineering



Performance data

N=3	Starting material	Isolated cells	
		Purity (%)	Viability (%)
Healthy donor	39.5% ± 9.9%	83.0% ± 10.8%	98% ± 0%

Table 2: Cell separation performance data for CD4⁺/CD8⁺ T cells.
(Data from Alzubi, J. & Lock, D. *et al.* (2020))

N=3	Start of cultivation	Final cell product			
	Number of seeded CD4 ⁺ /CD8 ⁺ T cells	Number of harvested CD4 ⁺ /CD8 ⁺ T cells	CAR ⁺ cells (%)	TCR ko cells (%)	Viability (%)
Healthy donor	2.1×10 ⁸ ± 0.47×10 ⁹	2.24×10 ⁹ ± 1.46×10 ⁹	52.5% ± 17.6%	34.4% ± 12.8%	93.3% ± 4.16%

Table 3: Cultivation and gene-editing performance data after viral transduction with the CAR and electroporation to knock out the endogenous TCR
(Data from Alzubi, J. & Lock, D. *et al.* (2020)).




Figure 1: Total cell count over the whole manufacturing process (n=3). Cell numbers are dropping significantly after electroporation-induced stress on day three. However, cell numbers recover quickly afterwards (Data from Alzubi, J. & Lock, D. *et al.* (2020)).




Figure 2: Viability of T cells after successful gene-editing using the CliniMACS Electroporator. After the electroporation step at day three cell viability is slightly decreased. At day six viability is already over 95% again (Data from Alzubi, J. & Lock, D. *et al.* (2020)).

References

Alzubi, J. & Lock, D. *et al.* (2020) Automated generation of gene-edited CAR T cells at clinical scale. *Molecular Therapy – Methods & Clinical Development* 20: 379–388.



Miltenyi Biotec B.V. & Co. KG | Phone +49 2204 8306-0 | Fax +49 2204 85197 | macsde@miltenyi.com | www.miltenyibiotec.com

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.

MACS GMP Products are for research use and *ex vivo* cell culture processing only, and are not intended for human *in vivo* applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans, the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC (“human tissues and cells”), or the Directive 2002/98/EC (“human blood and blood components”) – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval. CliniMACS GMP MicroBeads are for research use and *ex vivo* cell processing only. CliniMACS, CliniMACS Prodigy, MACS, TexMACS, TransAct, and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide.

Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.